CN101854916A - 由凝胶持续递送坎普他汀类似物 - Google Patents

由凝胶持续递送坎普他汀类似物 Download PDF

Info

Publication number
CN101854916A
CN101854916A CN200880115155A CN200880115155A CN101854916A CN 101854916 A CN101854916 A CN 101854916A CN 200880115155 A CN200880115155 A CN 200880115155A CN 200880115155 A CN200880115155 A CN 200880115155A CN 101854916 A CN101854916 A CN 101854916A
Authority
CN
China
Prior art keywords
compstatin analogs
fluid composition
compstatin
analogs
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880115155A
Other languages
English (en)
Chinese (zh)
Inventor
塞德里克·弗朗索瓦
帕斯卡尔·德沙特莱
保罗·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of CN101854916A publication Critical patent/CN101854916A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN200880115155A 2007-10-02 2008-10-02 由凝胶持续递送坎普他汀类似物 Pending CN101854916A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (1)

Publication Number Publication Date
CN101854916A true CN101854916A (zh) 2010-10-06

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880115155A Pending CN101854916A (zh) 2007-10-02 2008-10-02 由凝胶持续递送坎普他汀类似物

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20100094453A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
NZ607103A (en) 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
ES2426603T3 (es) 2010-09-03 2013-10-24 Novagali Pharma S.A. Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
JP6522337B2 (ja) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
EP3524258B1 (en) * 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US20160067357A1 (en) * 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
PT2920201T (pt) 2012-11-15 2020-04-03 Apellis Pharmaceuticals Inc Análogos de compstatina de longa ação e composições e métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
MX392574B (es) * 2015-10-07 2025-03-24 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares
RS60134B1 (sr) 2015-12-16 2020-05-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
MA51162A (fr) * 2017-12-15 2020-10-21 Apellis Pharmaceuticals Inc Schémas posologiques et compositions et procédés associés

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2373649T3 (es) * 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
CN105582523B (zh) * 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
DK1960422T3 (da) * 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger
EP1963529A2 (en) * 2005-12-22 2008-09-03 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
DK2148691T3 (en) * 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system

Also Published As

Publication number Publication date
US20110182877A1 (en) 2011-07-28
JP2010540654A (ja) 2010-12-24
WO2009046198A2 (en) 2009-04-09
AU2008308657A1 (en) 2009-04-09
KR20150080007A (ko) 2015-07-08
KR20100094453A (ko) 2010-08-26
WO2009046198A3 (en) 2009-07-16
MX2010003630A (es) 2010-04-21
RU2010113513A (ru) 2011-11-10
EP2207530A4 (en) 2013-09-11
CA2701470A1 (en) 2009-04-09
RU2505311C2 (ru) 2014-01-27
EP2207530A2 (en) 2010-07-21
ZA201002365B (en) 2010-12-29
BRPI0817524A2 (pt) 2017-05-02

Similar Documents

Publication Publication Date Title
CN101854916A (zh) 由凝胶持续递送坎普他汀类似物
CN105582523B (zh) 用于眼部病症的补体抑制素和其类似物
US10407466B2 (en) Methods of selecting compstatin mimetics
JP6522337B2 (ja) 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP7091373B2 (ja) 改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
JP2024123077A (ja) Ｃ３ｂ結合ポリペプチド
AU2016253654A1 (en) Injectable combination therapy for eye disorders
TW202214285A (zh) 治療眼病之方法
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares
HK1121380A (en) Compstatin and analogs thereof for eye disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101006